Prostate Cancer Foundation of Australia’s Post

💸 Biotech and pharma fundraising ended August quietly with 4 notable deals. See below to find out who was raising money this week…👇 🔬 (8/26) Diakonos Oncology closed an oversubscribed $11.4M seed financing to advance their dendritic cell vaccine, DOC1021, into a Phase 2 trial for glioblastoma and support ongoing trials for pancreatic cancer and angiosarcoma. 🧫 (8/27) ZBiotics raised $12M in an oversubscribed Series A to expand retail presence and develop new genetically engineered probiotics, building on their flagship Pre-Alcohol Probiotic Drink that helps break down acetaldehyde. 🎯 (8/28) Navigator Medicines secured a $100M Series A to advance NAV-240, a clinical-stage bispecific antibody targeting OX40L and TNFα, for autoimmune diseases. 🧬 (8/29) NOETIK secured $40M in an oversubscribed Series A to expand their spatial omics-based cancer atlas and CRISPR Perturb-Map platform, advancing their AI-driven cancer therapeutics pipeline.

U of A spinoff company Pacylex Pharmaceuticals, Inc., co-founded by Dr. John Mackey, Dr. Luc Berthiaume and Ryan Heit, is raising money to fund Phase 2 clinical trials of its new approach to cancer treatment. The odds are against any new drug getting to this stage, according to Dr. Mackey. Read via Folio: https://bit.ly/4f5GV93 Alberta Cancer Foundation The Cure Cancer Foundation Alberta Innovates National Research Council Canada / Conseil national de recherches Canada

Exciting news from Pacylex Pharmaceuticals, Inc.! 🌟 The University of Alberta spinoff is raising funds to advance its innovative cancer treatment through Phase 2 clinical trials. This is a major step toward bringing a potentially game-changing solution to cancer patients. “We want to let people — donors, investors and other investigators — know that it is possible to do translational research in Alberta, that you can go from the idea, the results in the lab, and translate that into a medicine that can be used by patients,” says company co-founder Luc Berthiaume. We’re excited to see how Pacylex continues to lead the way in cancer research and drug development! #CancerResearch #Innovation #lifesciences

We are not sure what is more amazing: the advancements in research and development introducing drug therapies, protocols, and possible cures for cancer, or the much-needed awareness of what cancer is often linked to from the start: #anemia. The most difficult roads in life always have a start. Sadly, when we don't bring the same measure of awareness to the beginnings of a health challenge, we don't do justice to the end. We hope to encourage all medical centers, #pharmaceutical companies, and healthcare personnel to support Patient Blood Management #pbm in dealing with the enemy of #cancer. If anemia is allowed to continue to take away a person’s energy in life, then the fight against cancer can become one of the most challenging experiences. Let's come together and fight this double challenge of awareness as one. Our insignia will serve as a reminder to the patient that you, as the healthcare advisor and provider, not only understand the relationship of Patient Blood Management and anemia to the fight against cancer, but that you are truly on their side. We are not interested in any donations. Use your donations and grants for more Cancer research. Awareness is more valuable, and so will our simple insignia anemia awareness placed on your white coat. Please feel free to contact us for more details.

Dear Stocktwits CEO Howard Lindzon: LinkedIn temporarily banned me last week for promoting Stocktwits (and, subsequently, calling for REAL Change on behalf of all Karyopharm Shareholders at Karyopharm Therapeutics Inc. and to save Karyopharm Medical Affairs). Uncle Rolli Greer, Jennifer M. Little-Vito, and I could not be more FULLY ALIGNED. We want the CEO, Richard Paulson, to step down. He has mismanaged the company. Everyone at KPTI knows this. And Stocktwits India 🇮🇳 users know it, too. (Just Google it or check Cafepharma, Inc!). I started buying shares at 69 cents per share. I have now sold most of mine and am down to a small 30K stake in my IRA (thanks to our hard work, KPTI jumped to 90 cents a share - but it has hit a wall because, well, nothing ever changes if nothing ever changes Richard, Garen Bohlin, and Barry Greene! Why are you still on the board with Dr Mansoor? Patricia Judson is the best candidate to run the Endometrial trials. Why is XPOVIO® (selinexor) HCP not being studied in a small, cost effective Phase 2 clinical trial to see if it can help Cure Glioblastoma? Why is Richard busy donating money to the Patrick Dempsy Foundation - a charity that has NOTHING to do with Multiple Myeloma, Myelofibrosis Neoplasms, The Endometrial Cancer Foundation, or the The Leukemia & Lymphoma Society? Why does Patrick Dempsy - who is a television actor worth millions - not buying shares of KPTI in return? Who the heck is supposed to be the firm responsible for auditing KPTI? The Internal Revenue Service is slacking here. Thanks 😎 ~Jeffrey Jay Conroy 🎍 Global HC Analytics LLC, Founder & Oncology CI & Forecasting Expert 🏉

Such exciting news for the NK space as Indapta announce their new funding secured, helping them to advance their clinical trials in g-NK cells in Oncology and continue funding their first Autoimmune clinical trial!

We are pleased to share that the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the funding of Rybrevant® (amivantamab) for Australians with EGFR Exon 20 insertion advanced non-small cell lung cancer. This is an aggressive, difficult-to-treat form of lung cancer that mostly impacts non-smoking women, many diagnosed at the prime of their lives. The PBAC’s recommendation for Rybrevant® is a promising step forward and we are now working with the government to progress a PBS listing.    Thank you to all members of Australia’s lung cancer community who advocated for this outcome.  At Johnson & Johnson Innovative Medicine ANZ, we are determined to continue collaborating in advancing treatment options and transforming outcomes for Australians impacted by this devastating disease. #JNJ #MyCompany #PBS #MedicinesAccess

We are delighted to announce the successful USD $25M first close of our Series B financing, and to welcome our new investor Bristol Myers Squibb as we continue to advance PTT-4256 into the clinic later this year. This Series B financing consists of a new strategic investment from Bristol Myers Squibb (BMS), as well as support from existing investors including Canaan and Brandon Capital. Proceeds from the raise will be used for the continued development of Pathios’ unique approach to cancer immunotherapy focused on the inhibition of GPR65, a novel target that has been genetically associated with a range of immunologically-mediated diseases. This investment comes at an exciting inflection point for Pathios as we progress GPR65 inhibitor PTT-4256 towards our first-in-human clinical trial. We'd like to thank the Pathios team and our collaborators for their incredible work, and our investors who continue to believe in our mission to transform cancer outcomes. To find out more, read the full press release here: https://lnkd.in/dp8XmQwX #fundraising #investment #GPR65 #biotech #clinicaltrials #drugdevelopment #immunotherapy #immunooncology

Major step toward global Actinium-225 cancer treatments! IBA and SCK CEN's joint venture PANTERA secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production. This is the largest fundraising in Belgium’s life sciences sector 🇧🇪 Founded in 2022, PANTERA's mission is to enable large-scale production of Actinium-225 (225Ac), a critical component for a new class of targeted cancer treatments known as Targeted Alpha Therapy. The funds raised will be used primarily to support the construction of a state-of-the-art production facility in Belgium. Sven Van den Berghe, CEO of PanTera, said: “With this funding, we are now en route to realise our vision of providing a “Better Fight for Life” to cancer patients worldwide by becoming a dependable global 225Ac supplier.” 👉 Read the full article: https://lnkd.in/eiDZCSr2

𝐓𝐨𝐠𝐞𝐭𝐡𝐞𝐫, 𝐰𝐞 𝐚𝐫𝐞 𝐬𝐭𝐫𝐨𝐧𝐠𝐞𝐫 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐢𝐠𝐡𝐭 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 - 𝐚 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐧𝐨 𝐨𝐧𝐞 𝐬𝐡𝐨𝐮𝐥𝐝 𝐟𝐚𝐜𝐞 𝐚𝐥𝐨𝐧𝐞. 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 serves as a crucial reminder that early detection, timely care and compassionate support can change lives. This year’s theme, 𝐍𝐨 𝐨𝐧𝐞 𝐬𝐡𝐨𝐮𝐥𝐝 𝐟𝐚𝐜𝐞 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 𝐚𝐥𝐨𝐧𝐞, emphasizes the importance of creating a community of care, ensuring that everyone has access to the support and resources they need to face this challenge with resilience. The Department of Pharmaceutical Management, NIPER S.A.S. Nagar (Mohali), stands in solidarity with all those affected by breast cancer. This October, we reaffirm our commitment to fostering awareness and supporting early detection efforts. Together, we aim to build a stronger, more compassionate community for all. #breastcancer #breastcancerawareness #october #cancer #dopm #niper #pharmaceutical #management